Lidocaine-d6 (hydrochloride)

Lidocaine-d6 (hydrochloride)

• CAS Number: 2517378-96-8
• UNSPSC Description: Lidocaine-d6 (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor[2].
• Target Antigen: Apoptosis; ERK; MEK; NF-κB; Sodium Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Apoptosis;MAPK/ERK Pathway;Membrane Transporter/Ion Channel;NF-κB;Stem Cell/Wnt
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer; Cardiovascular Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C(NC1=C(C([2H])([2H])[2H])C=CC=C1C([2H])([2H])[2H])CN(CC)CC.Cl
• Molecular Weight: 276.84
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11.|[3]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6.|[4]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported